All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Researchers at Hangzhou Glubio Therapeutics Co. Ltd. have patented isoindolinone molecular glue degraders that induce DNA-binding protein Ikaros (IKZF1) degradation and are reported to be useful for the treatment of cancer.
